Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study assessing antibody response and safety recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan

Next Previous
Trial Profile

Study assessing antibody response and safety recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozinameran (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 24 Jan 2023 New trial record
  • 01 Jan 2023 Results published in the Journal of the Formosan Medical Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top